Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030105 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
A Phase 1 study, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03030105: Completed Phase 1 study, sponsored by Tetra Discovery Partners.
NCT03030105 is a Phase 1 study that has completed, run by Tetra Discovery Partners. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030105, a Phase 1 study, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.
Interventions
- DRUG Donepezil
- DRUG BPN14770
- DRUG BPN14770 placebo
- DRUG Donepezil placebo
- DRUG Scopolamine 0.6 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030105
The ClinicalTrials.gov registry entry for NCT03030105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetra Discovery Partners, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Donepezil is the first listed.
NCT03030105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030105 about?
NCT03030105 is a clinical study titled "Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770...
What is the current status of trial NCT03030105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT03030105?
The interventions under investigation include: Donepezil (DRUG), BPN14770 (DRUG), BPN14770 placebo (DRUG), Donepezil placebo (DRUG), Scopolamine 0.6 MG/ML (DRUG).
Who is sponsoring clinical trial NCT03030105?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.